Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
| Pre-Market | Intra-Day | After-Hours |
|---|---|---|
| 128.40 (-0.01 / -0.01%) | 132.95 (4.54 / 3.54%) | - (- / -%) |
| 17-Apr 09:18 | 17-Apr 13:51 | 16-Apr 17:20 |
Sector: Healthcare || Industry: Drug Manufacturers - Specialty & Generic
| Previous Close | 128.41 | Year Low | 98.95 |
| Open | 129.00 | Year High | 160.18 |
| Day Low | 128.41 | Price Avg 50 | 130.86 |
| Day High | 133.54 | Price Avg 200 | 137.38 |
| Volume | 923.99 K | Market Cap | 13.34 B |
News
| Symbol | Catalyst News |
|---|---|
| NBIX | Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? Zacks Investment Research | 2026-04-15 15:36:13 Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 GuruFocus | 2026-04-14 17:41:00 |
Analysis
| Symbol | 1D | 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|---|---|
| NBIX | 3.54 | 0.70 | 1.71 | 0.42 | -5.10 | 31.14 |
Earnings
| Date | Time | Symbol | company_name | Period | Metric | Estimate | Actual | Surprise | YrAgo | Growth | sector_industry |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/11/2026 | AMC | NBIX | Neurocrine Biosciences | Q4 2025 | EPS | 1.89 | 1.88 | -0.53 | 1.69 | 11.20 | |
| 02/11/2026 | AMC | NBIX | Neurocrine Biosciences | Q4 2025 | REV | 792.47 M | 805.50 M | 1.64 | 627.70 M | 28.33 | |
| 10/28/2025 | AMC | NBIX | Neurocrine Biosciences | Q3 2025 | EPS | 1.59 | 2.17 | 36.48 | 1.81 | 19.90 | |
| 10/28/2025 | AMC | NBIX | Neurocrine Biosciences | Q3 2025 | REV | 746.05 M | 794.90 M | 6.55 | 622.10 M | 27.78 | |
| 07/30/2025 | AMC | NBIX | Neurocrine Biosciences | Q2 2025 | EPS | 0.95 | 1.65 | 73.68 | 1.63 | 1.20 | Industrials / Specialty Industrial Machinery |
| 07/30/2025 | AMC | NBIX | Neurocrine Biosciences | Q2 2025 | REV | 652.64 M | 687.50 M | 5.34 | 590.20 M | 16.49 | Industrials / Specialty Industrial Machinery |
| 05/05/2025 | AMC | NBIX | Neurocrine Biosciences | Q1 2025 | EPS | 0.54 | 0.70 | 29.63 | 1.20 | -41.70 | Healthcare / Drug Manufacturers—Specialty & Generic |
| 05/05/2025 | AMC | NBIX | Neurocrine Biosciences | Q1 2025 | REV | 559.33 M | 572.60 M | 2.37 | 515.30 M | 11.12 | Healthcare / Drug Manufacturers—Specialty & Generic |
Outlooks
| Date | Time | Symbol | Company | Period | Metric | Estimate | Outlook | Previous | Catalyst | list_link | eps_est | rev_est | cur_midpoint | pre_midpoint | Growth * | yrago_growth | pre_growth | company_sector | company_industry | ref_id | chart_code | history_code | sector_industry |
|---|
Ratings
| Date | Symbol | Analyst Firm | Rating Current | Rating Previous | Analyst Action |
|---|---|---|---|---|---|
| 04/07/2026 | NBIX | Wedbush | Outperform | Outperform | Maintain |
| 04/07/2026 | NBIX | HC Wainwright & Co. | Buy | Buy | Maintain |
| 04/07/2026 | NBIX | Citigroup | Buy | Buy | Maintain |
| 04/07/2026 | NBIX | Canaccord Genuity | Buy | Buy | Maintain |
| 04/06/2026 | NBIX | Needham | Buy | Buy | Maintain |
| 03/12/2026 | NBIX | JP Morgan | Overweight | Overweight | Maintain |
| 02/17/2026 | NBIX | JP Morgan | Overweight | Overweight | Maintain |
| 02/17/2026 | NBIX | Truist Securities | Buy | Buy | Maintain |
| 02/13/2026 | NBIX | Wells Fargo | Overweight | Overweight | Maintain |
| 02/12/2026 | NBIX | BMO Capital | Market Perform | Market Perform | Maintain |
Dividends
| Date | Symbol | Company | Type | Value | Yield | Record Date | Exch Date | Pay Date | Notes |
|---|
Sign-Up to see the full list of CATALYSTS in the Calendars